NCT00000632View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1992

Conditions

HIV InfectionsHIV Seronegativity

Interventions

BIOLOGICAL

Env 2-3

Trial Locations (3)

14642

Univ. of Rochester AVEG, Rochester

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

981050371

UW - Seattle AVEG, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biocine

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH